Healthcare -
Drug Manufacturers - Specialty & Generic - NASDAQ - CA
$ 4.275
-5.41 %
$ 235 M
Market Cap
22.11
P/E
1. INTRINSIC VALUE
Balance Sheet
Aurora Cannabis Inc.
| Current Assets | 427 M |
| Cash & Short-Term Investments | 117 M |
| Receivables | 45.4 M |
| Other Current Assets | 264 M |
| Non-Current Assets | 412 M |
| Long-Term Investments | 6.34 M |
| PP&E | 294 M |
| Other Non-Current Assets | 111 M |
| Current Liabilities | 125 M |
| Accounts Payable | 20.3 M |
| Short-Term Debt | 57.2 M |
| Other Current Liabilities | 47.1 M |
| Non-Current Liabilities | 112 M |
| Long-Term Debt | 47.6 M |
| Other Non-Current Liabilities | 64.6 M |
EFFICIENCY
Earnings Waterfall
Aurora Cannabis Inc.
| Revenue | 270 M |
| Cost Of Revenue | 139 M |
| Gross Profit | 131 M |
| Operating Expenses | 178 M |
| Operating Income | -46.5 M |
| Other Expenses | 12.6 M |
| Net Income | -59 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Aurora Cannabis Inc.
| Net Income | -59 M |
| Depreciation & Amortization | 33.1 M |
| Capital Expenditures | -17 M |
| Stock-Based Compensation | 12.7 M |
| Change in Working Capital | -15.6 M |
| Others | -70.7 M |
| Free Cash Flow | -85.5 M |
Wall Street Analysts Price Targets
Aurora Cannabis Inc.
Wall Street analysts predict an average 1-year price target for ACB of $6.67 , with forecasts ranging from
a
low of
$1 to a high of $11 .
ACB Lowest Price Target
Wall Street Target
1 USD
-76.61%
ACB Average Price Target
Wall Street Target
6.67 USD
55.95%
ACB Highest Price Target
Wall Street Target
11 USD
157.31%
4. DIVIDEND
ANALYSIS
ACB does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Aurora Cannabis Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
3 Canadian Marijuana Stocks That Could See Big Future Gains
When it comes to finding marijuana stocks to buy a happy medium or silver lining at this time is tough to do. Not becuase the low share prices from some of the top-performing companies dont look appetizing. It is more due to the consistent falls in the sector no real upward push. Even as the cannabis industry as a whole is thriving and showing great long-term success.
marijuanastocks.com
- 2 weeks ago
Aurora Cannabis Introduces the Company's First Inhalable Resin Cartridges for Patients in the United Kingdom
NASDAQ | TSX: ACB Canada's Leading Medical Cannabis Company Expands Patient Offering with Innovative Dosage Solution EDMONTON, AB , April 15, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, has announced today the availability of medical cannabis concentrates to patients in the United Kingdom (UK). This launch marks the company's meaningful step in offering its proprietary cultivar-specific inhalable cannabis extracts in the UK market.
prnewswire.com
- 2 weeks ago
Aurora Cannabis Recognized for Executive Gender Diversity by The Globe and Mail
Canada's Largest Medical Cannabis Company is an Honouree in The Globe and Mail's 2025 Report on Business Magazine's sixth annual Women Lead Here List EDMONTON, AB , March 31, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, has been named an honouree on the Globe & Mail's 2025 Report on Business, Women Lead Here list. This annual editorial benchmark recognizes the top publicly traded Canadian companies with the highest gender diversity at the executive level.
prnewswire.com
- 1 month ago
Top Canadian Cannabis Stocks to Watch in April 2025
Top Canadian cannabis stocks are attracting attention this week as investors seek opportunities in a rapidly evolving industry. Companies like Cronos Group, SNDL Inc., and Aurora Cannabis continue strengthening their positions in Canadian and international markets. Though based in Canada, these firms have exposure to the U.S. through strategic investments and partnerships. The U.S. cannabis industry is expected to generate over $45 billion annually by 2025. Legalization efforts are expanding, and several states are reviewing new adult-use and medical cannabis bills. At the same time, court rulings and state-level decisions continue to shape the legal landscape. Because of this, Canadian companies with U.S. exposure are drawing increased interest from traders and long-term investors alike.
marijuanastocks.com
- 1 month ago
Ethos Cannabis Expands Pennsylvania Presence with Aurora Launch and Title Sponsorship at the Pennsylvania Cannabis Convention
MSO Unveils Premium Infused Live Resin Flower and Leads Industry Conversations at Pennsylvania Cannabis Convention MSO Unveils Premium Infused Live Resin Flower and Leads Industry Conversations at Pennsylvania Cannabis Convention
globenewswire.com
- 1 month ago
Aurora Cannabis to Speak at the Global Cannabis Regulatory Summit
NASDAQ | TSX: ACB Canada's Largest Medical Cannabis Company to Participate as an Industry Leader in the Inaugural Regulatory Event in Washington, D.C. EDMONTON, AB , March 25, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to be attending, sponsoring and speaking at the 2025 Global Cannabis Regulatory Summit (GCRS), held within the U.S. Capitol Complex in Washington, D.C.
prnewswire.com
- 1 month ago
Aurora Cannabis Announces Breakthrough Discovery of Powdery Mildew Resistant Cultivars
NASDAQ | TSX: ACB Groundbreaking research at Aurora Coast, Aurora's world-class research and development facility, sets new standard in cannabis science EDMONTON, AB , March 20, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to announce the Company's discovery of a novel source of genetic resistance against powdery mildew, PM2, that provides strong protection against this pathogen in cannabis sativa. The development of this proprietary genetic marker technology, which is now in use in Aurora's breeding program, is set to produce powdery mildew resistant cultivars that will be explored for commercial launch this year.
prnewswire.com
- 1 month ago
3 Canadian Marijuana Stocks To Watch For Future Gains 2025
Marijuana stocks have been facing a downward trend in the market for some time. A big reason is regulatory uncertainty and reform issues. Legislative changes, particularly in major markets like the U.S., can greatly affect how shareholders think. Additionally, oversupply in certain regions has led to falling prices, which negatively affects revenue for companies in the sector. This has created a volatile sector where the trading behavior of the most public companies is more on the low end.
marijuanastocks.com
- 1 month ago
Aurora Cannabis Rides the Global Legalization Wave: Should You Invest?
ACB capitalizes on the rapidly evolving medical cannabis landscape, leveraging its EU GMP-certified manufacturing facilities, advanced genetics and deep regulatory knowledge.
zacks.com
- 1 month ago
Are Medical Stocks Lagging Aurora Cannabis (ACB) This Year?
Here is how Aurora Cannabis Inc. (ACB) and Concentra Group (CON) have performed compared to their sector so far this year.
zacks.com
- 1 month ago
High-Potential Canadian Cannabis Stocks to Watch This Month
The Canadian cannabis sector remains a key player in the global market. Many top Canadian companies are expanding into the U.S. in anticipation of future federal legalization. The U.S. cannabis industry continues to grow rapidly, with sales expected to surpass $40 billion in 2025. More states are legalizing cannabis, increasing market opportunities for Canadian producers. Recently, lawmakers introduced new federal reform bills that could ease banking restrictions and boost industry expansion. Investors are closely watching these developments as they could impact stock performance. With growing demand and regulatory progress, top Canadian cannabis stocks remain attractive.
marijuanastocks.com
- 1 month ago
Investing in Cannabis: Best Canadian Stocks to Watch in March 2025
The Canadian cannabis sector continues to evolve as companies expand operations and navigate industry challenges. Many Canadian cannabis producers are looking beyond their domestic market and establishing strong positions in the U.S. Despite federal restrictions. Some have developed partnerships, investments, or business strategies that position them well for eventual legalization.
marijuanastocks.com
- 1 month ago
8. Profile
Summary
Aurora Cannabis Inc. ACB
COUNTRY
CA
INDUSTRY
Drug Manufacturers - Specialty & Generic
MARKET CAP
$ 235 M
Dividend Yield
0.00%
Description
Aurora Cannabis Inc. produces, distributes, and sells cannabis and cannabis derivative products in Canada and internationally. It also engages in facility engineering and design, cannabis breeding, research, production, derivatives, product development, wholesale, and retail distribution activities. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients. It also sells vaporizers; consumable vaporizer accessories; and herb mills for using CanniMed herbal cannabis products, as well as grinders and vaporizer lockable containers. In addition, the company engages in the development of medical cannabis products at various stages of development, including oral, topical, edible, and inhalable products; and operation of CanvasRX, a network of cannabis counseling and outreach centers. Further, it provides patient counselling services; design and construction services; and cannabis analytical product testing services. The company's brand portfolio includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.
Contact
500 - 10355 Jasper Avenue, Edmonton, AB, T5J 1Y6
https://www.auroramj.com
IPO
Date
July 15, 2014
Employees
1073
Officers
Ms. Simona King CPA
Chief Financial Officer
Ms. Nathalie Clark
Executive Vice President, General Counsel & Corporate Secretary
Michelle Lefler
Vice President of Communications & Public Relations
Dr. Jonathan Page Ph.D.
Senior Science Advisor
Mr. Andre Jerome
Executive Vice President of Global Business Development
Mr. Alex Miller
Executive Vice President of Operations & Supply Chain
Ms. Lori Schick
Executive Vice President of Human Resources
Mr. Rick Savone
Senior Vice President of Global Government Relations
Mr. Ananth Krishnan
Vice President of Capital Markets & Investor Relations
Mr. Miguel Martin
Chief Executive Officer & Executive Chairman